In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care. We also present a meta-analysis of similar observational studies available in the literature. In our multicentre retrospective study, patients initiating ExeOW (n = 204) or liraglutide (n = 410) had similar baseline clinical characteristics. Change in HbA1c at 6 months was superimposable in the two groups (−0.7% ± 1.0%), and changes in body weight were also similar (ExeOW -2.2 ± 3.7 kg; liraglutide −2.5 ± 4.3 kg; p = 0.457). Discontinuation rates were numerically but not significantly lower for ExeOW versus liraglutide. Pooling these data with those of observational studies available in the literature yielded superimposable effects between the two groups for the change in HbA1c and body weight, with a higher risk of discontinuation (mainly based on pharmacy refill rates) for ExeOW. We conclude that, in patients under routine care, initiation of ExeOW provides similar benefits on HbA1c and body weight as initiation of liraglutide.
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These data help view the results of randomized controlled trials from the perspective of their application in routine clinical practice.
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| INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in biochemical structure and pharmacokinetics, with injection schedules ranging from twice daily to once weekly (OW). In randomized controlled trials (RCTs) in patients with type 2 diabetes (T2D), GLP-1RA improved glucose control, body weight, blood pressure and serum lipids. 1 Because of these effects on multiple cardiovascular risk factors, GLP-1RAs have great potential for protection against cardiovascular disease. This has been confirmed by RCTs showing reduction of major adverse cardiovascular events (MACE) with once-daily liraglutide and OW semaglutide and albiglutide. [2] [3] [4] The RCTs evaluating exenatide OW (ExeOW) reported a nearly significant reduction in MACE (P = 0.06) and a reduction in all-cause mortality (P = 0.016).
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Based on this evidence, treatment guidelines recommend GLP-1RAs
for cardiovascular protection in T2D. 6 According to a network meta-analysis, some differences in the glucose-lowering potency of the various GLP-1RAs may exist. 7 In the DURATION-6 trial, liraglutide 1.8 mg was superior to ExeOW in reducing HbA1c. 8 However, the 1.8 mg liraglutide dose is often not reached in clinical practice and is not recommended by some guidelines, 9 such that it remains unclear whether liraglutide and ExeOW differ in their glucose-lowering capacity in the real world.
Since data coming from routine clinical practice can complement RCT findings, 10 we compared the effectiveness of liraglutide and ExeOW in a retrospective study conducted in diabetes outpatient clinics in Italy. 11 To view the results from the perspective of the available literature, we also performed a meta-analysis of observational studies comparing liraglutide and ExeOW.
2 | METHODS
| Study design and data extraction
The DARWIN-T2D was a retrospective multicentre study on data of patients initiating dapagliflozin, a dipeptidyl peptidase-4 (DPP-4) Drug discontinuation was defined when the drug was no longer prescribed at follow-up. Reasons for discontinuation, as well as information on side effects, including hypoglycaemia, were not available.
| Statistical analysis
Continuous data are presented as mean ± standard deviation, while categorical data are presented as percentages. Normality of continuous variables was checked using the Kolmogorov-Smirnov test and non-normal variables were log-transformed before analysis. Betweengroup differences in baseline variables were evaluated using unpaired 2-tail Student's test for continuous variables and chi-square test for categorical variables. In addition to P-values, we report the standardized difference as a mean to evaluate the balance between groups. In the presence of P < 0.05, a standardized difference > 0.10 was considered suggestive of clinically relevant imbalance. Within-group differences in effectiveness endpoints were assessed using paired 2-tail Student's t test. Changes from baseline to follow-up in effectiveness variables were computed in each group and compared using unpaired 2-tail Student's test. To account for selection bias and adjust for eventual imbalanced variables, a multiple linear regression was planned with the desired effectiveness endpoint as the dependent variable and covariate(s) as independent variable(s). Statistical significance was accepted at P < 0.05 and SPSS v.21 or higher was used. Methods of the meta-analysis are given in the online Appendix S1 (see the supporting information for this article).
3 | RESULTS
| Patients' characteristics
During the study period, 2247 T2D patients initiated a GLP-1RA; after excluding patients without a follow-up visit and those who were on insulin, the study included 410 patients on liraglutide and 204 patients on ExeOW ( Figure S1A ). The two groups were well balanced for age, sex, diabetes duration, body mass index (BMI), blood pressure, fasting glucose, HbA1c, renal function, concomitant and lifetime use of other GLM (Table S1 ). This allowed a direct comparison of the effectiveness of ExeOW versus liraglutide. However, 10% less of patients in the ExeOW group versus the liraglutide group were on angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ACEi/ARBs; P = 0.005). Table S1B shows the differences between patients with and without a follow-up visit. Table S2 summarizes effectiveness results. After an average follow-up of 5.6 months in both groups (median 5.9; interquartile range 4.2-6.4), HbA1c declined significantly from 7.7% ± 0.8% to 7.0% ± 0.9% in the liraglutide group and from 7.6% ± 0.9% to 6.9% ± 0.9% in the ExeOW group. The change from baseline in HbA1c between the two groups was not significantly different (−0.7% ± 1.0% vs. −0.7% ± 1.0%; P = 0.752; Figure 1A ). At follow-up, 56.4% of patients in the ExeOW group versus 50.4% in the liraglutide group reached HbA1c < 7.0% (Table S3) .
| Effectiveness
Total cholesterol and LDL cholesterol levels improved significantly during treatment with both liraglutide and ExeOW and the changes from baseline were not significantly different between groups. The reduction of liver enzymes was also similar between the two groups. Also, eGFR and AER did not change during treatment of either GLP-1RA.
| Discontinuation
The rate of discontinuation was 8.7% in the liraglutide group versus 6.8% in the ExeOW group (P = 0.41). The corresponding projected yearly discontinuation rates were 18.4% and 14.5%, respectively.
| Meta-analysis
We identified 13 real world observational studies (Figure 2A Figure 2B ] or for the change in body weight (0.12 kg; 95% CI -0.26; 0.51; no heterogeneity, Figure 2C ). The pooled risk ratio of discontinuation was 1.22 (95% CI 1.07; 1.39),
indicative of a higher likelihood of discontinuation with ExeOW than with liraglutide, but with very high heterogeneity among studies ( Figure 2D ).
| DISCUSSION
We show that, in the routine clinical treatment of T2D patients who were uncontrolled on oral agents, initiation of ExeOW provided similar reductions in HbA1c and body weight to initiation of liraglutide.
These results are consistent with those of other studies included in the meta-analysis, but contrast with results of the head-to-head comparative trial DURATION-6, 8 as summarized in Table S4 . In DURATION-6, the magnitude of HbA1c reduction at 6 months was larger (−1.48% with liraglutide and − 1.28% with ExeOW) and liraglutide, uptitrated to the maximum dose of 1.8 mg in all patients, reduced HbA1c more than ExeOW. The higher average HbA1c reduction in the DURATION-6 trial than in our real-world study could be explained by the higher baseline HbA1c (8.4-8.5%
vs. 7.6-7.7%, respectively). Indeed, the percentages of patients reaching HbA1c < 7.0% was similar in the trial to the real world. The use of ExeOW versus liraglutide may increase patient compliance and adherence, because of the need for less injections. In our study, the rate of permanent discontinuation at~6 months was nominally, but not significantly, lower with ExeOW than with liraglutide.
Rates of discontinuation at 6 or 12 months in other studies in the literature, defined based on drug pharmacy refill rates, were higher with 
